LBT
vs
S
S&P/ASX 300

Over the past 12 months, LBT has underperformed S&P/ASX 300, delivering a return of +6% compared to the S&P/ASX 300's +9% growth.
Stocks Performance
LBT vs S&P/ASX 300
Performance Gap
LBT vs S&P/ASX 300
Performance By Year
LBT vs S&P/ASX 300
LBT Innovations Ltd
Glance View
LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia. The company went IPO on 2006-07-31. The firm is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The firm's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The firm's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.
